Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 03 May, 2019

Winchester MD Ltd

Winchester MD attends First Wednesday

RNS Number : 0882Y
Winchester MD Limited
03 May 2019
 

 

WINCHESTER ATTENDS FIRST WEDNESDAYS - THE EUROPEAN CANNABIS PROFESSIONAL NETWORK

 

LONDON, UK, May 2, 2019 - WINCHESTER MD LIMITED ("Winchester" or the "Company") attended the First Wednesday Cannabis Professional Network event on May 1, 2019  in London, UK sponsored by Canaccord and DAC Beachcroft. First Wednesdays is powered by Hanway Associates, London's global cannabis consultancy - your knowledge & network partner. London hosts include Canaccord Genuity Limited's Head of European Cannabis Investment banking team, Tristan Gervais, as well as other.

 

"The evening is brimming with a slightly breathless, nothing-can-stop-us zeal - a brand of enthusiasm I recognise from the years I spent in California covering Silicon Valley for this magazine." - Rhys Blakely, The Times

 

Faz, CEO of Winchester, commented "This is a great event for entrepreneurs and is held on the first Wednesday of every month. The cannabis industry in Europe has been evolving at a rapid speed and events like this bring like minded people together to discuss challenges and opportunities facing all of us in the global legalization of Cannabis. Our team at Winchester strives to continuously adapt our business model with the changes in legalization while maintaining quality products for our customers who order through our on-line CBD Wellness retail platform www.hempelf.com."

 

In attendance at the event were Faz Moshfeghi, CEO Winchester Corporate, Marti Moshfeghi, CEO Winchester CBD Wellness, Dan Kriznic VP Public Markets and Business Development and Mike Kriznic, Italy Country manager.

 

 

For more information, please visit www.winchestermd.com

 

On Behalf of the Board,

Faz Moshfeghi

CEO

[email protected]

 

About Winchester MD Limited

 

Winchester is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD products through its on line store and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector including with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness, R&D and clinics/education

 

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

 

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

 

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRALLFIEESIVIIA

a d v e r t i s e m e n t